tiprankstipranks
Advertisement
Advertisement
KROMATID Emphasizes Genomic Integrity Focus in AAV Gene Therapy Development
PremiumPrivate CompaniesKROMATID Emphasizes Genomic Integrity Focus in AAV Gene Therapy Development
7d ago
KROMATID – Weekly Recap
Premium
Private Companies
KROMATID – Weekly Recap
10d ago
KROMATID Showcases Genomic Instability Analytics for Gene-Edited Cell Therapies
Premium
Private Companies
KROMATID Showcases Genomic Instability Analytics for Gene-Edited Cell Therapies
14d ago
KROMATID Leverages ASGCT and ISCT Platforms to Advance Genomic Intelligence Strategy
PremiumPrivate CompaniesKROMATID Leverages ASGCT and ISCT Platforms to Advance Genomic Intelligence Strategy
24d ago
KROMATID Highlights Genomic Integrity Toolbox for Gene-Edited Cell Therapies at ASGCT
Premium
Private Companies
KROMATID Highlights Genomic Integrity Toolbox for Gene-Edited Cell Therapies at ASGCT
26d ago
KROMATID Highlights Genomic Integrity Framework Ahead of ASGCT 2026
Premium
Private Companies
KROMATID Highlights Genomic Integrity Framework Ahead of ASGCT 2026
26d ago
KROMATID Highlights Advanced Cytogenetic Platform for Cell and Gene Therapy Workflows
PremiumPrivate CompaniesKROMATID Highlights Advanced Cytogenetic Platform for Cell and Gene Therapy Workflows
27d ago
KROMATID Showcases Genomic Instability Benchmarking Work at ASGCT
Premium
Private Companies
KROMATID Showcases Genomic Instability Benchmarking Work at ASGCT
28d ago
KROMATID Highlights Genomic Instability Benchmarking Work in Gene-Edited Cell Therapies
Premium
Private Companies
KROMATID Highlights Genomic Instability Benchmarking Work in Gene-Edited Cell Therapies
28d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100